If macrolide resistance is common in the community, what is an appropriate outpatient alternative for CAP?

• A. Doxycycline 100 mg twice daily or a respiratory fluoroquinolone (e.g., levofloxacin) if indicated.
• B. Amoxicillin only.
• C. Cefdinir.
• D. Macrolide plus beta-lactam.

Answer: (A)

When macrolide resistance is common in the community, relying on a macrolide alone for outpatient CAP therapy is less reliable because the usual pathogens (like Streptococcus pneumoniae) may not be covered effectively. Doxycycline is a good alternative because it provides reliable coverage of typical bacteria and also covers atypical pathogens such as Mycoplasma and Chlamydophila, which are common causes of CAP. A respiratory fluoroquinolone (such as levofloxacin) is another option when indicated, offering broad coverage of both typical and atypical organisms and is especially considered for patients with comorbidities or higher risk where using other options might be insufficient.

Amoxicillin alone misses atypical pathogens, so it isn’t ideal when macrolide resistance is a concern. Cefdinir covers many pneumococci but is less reliable for atypicals. A macrolide plus beta-lactam still relies on macrolide activity, which is less dependable in a resistant setting.

Therefore, the best outpatient choices are doxycycline or a respiratory fluoroquinolone if indicated.